晚期黑色素瘤患者免疫检查点抑制剂与靶向治疗失败后抗PD-(L)1联合BRAF/MEK抑制剂(三联疗法)的疗效
这项回顾性多中心研究纳入48例晚期黑色素瘤患者,均在至少一种抗PD-(L)1治疗和一种靶向治疗失败后接受BRAF/MEK抑制剂联合抗PD-(L)1抗体(三联疗法)。结果显示客观缓解率为35.4%,疾病控制率为47.9%,中位缓解持续时间为5.9个月,3-4级治疗相关不良事件发生率为25%。作者认为三联疗法在经重度治疗的晚期黑色素瘤患者中显示出活性,可能代表ICI和TT失败后的一种潜在治疗方案。
要点
- 三联疗法在ICI和TT失败后的晚期黑色素瘤中ORR为35.4%,DCR为47.9%。
- 中位DOR为5.9个月,3-4级治疗相关不良事件发生率为25%。
- 作者认为三联疗法可能代表ICI和TT失败后的一种潜在治疗方案。
核心结论
- 三联疗法在经重度治疗的晚期黑色素瘤患者中显示出活性,可能代表ICI和TT失败后的一种潜在治疗方案。
研究设计与样本
- 回顾性、多中心研究,纳入2016年2月至2022年7月期间在七家主要黑色素瘤中心接受BRAF/MEK抑制剂联合抗PD-(L)1抗体(三联疗法)的晚期黑色素瘤患者,这些患者至少一种抗PD-(L)1为基础的治疗和一种靶向治疗失败。
- 共纳入48例患者。
主要发现
- 32例患者(66.7%)有脑转移,37例患者(77.1%)有三个或以上转移器官,21例患者(43.8%)接受过三线或以上治疗。
- 中位随访时间为31.4个月(IQR,22.27-40.45个月)。
- 三联治疗的ORR为35.4%(n=17),DCR为47.9%(n=23)。
- 中位DOR为5.9个月(范围,3.39-14.27个月)。
- 以BRAF/MEK抑制剂为末线治疗的患者ORR为29.6%,略低于末线接受ICI或化疗的患者(ORR:42.9%)。
临床怎么用
- 作者认为三联疗法可能代表ICI和TT失败后的一种潜在治疗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effective treatment options are limited for patients with advanced melanoma who have progressed on immune checkpoint inhibitors (ICI) and targeted therapies (TT). Preclinical models support the combination of ICI with TT; however, clinical trials evaluating the efficacy of triplet combinations in first-line setting showed limited advantage compared to TT only. METHODS: We conducted a retrospective, multicenter study, that included patients with advanced melanoma who were treated with BRAF/MEK inhibitors in combination with an anti-PD-(L)1 antibody (triplet therapy) after failure of at least one anti-PD-(L)1-based therapy and one TT in seven major melanoma centers between February 2016 and July 2022. RESULTS: A total of 48 patients were included, of which 32 patients, 66.7% had brain metastases, 37 patients (77.1%) had three or more metastatic organs and 21 patients (43.8%) had three or more treatment lines. The median follow-up time was 31.4 months (IQR, 22.27-40.45 months). The treatment with triplet therapy resulted in an ORR of 35.4% (n = 17) and a DCR of 47.9% (n = 23). The median DOR was 5.9 months (range, 3.39-14.27 months). Patients treated with BRAF/MEK inhibitors as the last treatment line showed a slightly lower ORR (29.6%) compared to patients who received ICI or chemotherapy last (ORR: 42.9%). Grade 3-4 treatment-related adverse events occurred in 25% of patients (n = 12), with seven patients (14.6%) requiring discontinuation of treatment with both or either drug. CONCLUSIONS: Triplet therapy has shown activity in heavily pretreated patients with advanced melanoma and may represent a potential treatment regimen after failure of ICI and TT.
引用
- Albrecht LJ, Dimitriou F, Grover P, et al. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. Eur J Cancer. 2024. PMID: 38484692. doi:10.1016/j.ejca.2024.113976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。